Abstract
Aims: Atractylodes macrocephala is a traditional Chinese medicine with a variety of pharmacological activities. This study aimed to evaluate its anti-hyperuricemia and antiinflammatory effects on gout, and to preliminarily explore its mechanism.
Methods: The hyperuricemia rat model was established by intraperitoneal injection of oteracil potassium and intragastric gavage of yeast powder solution. And the acute gouty arthritis (GA) model was established by injecting monosodium urate (MSU) suspension. In the study of the antihyperuricemia effect of Atractylodes macrocephala, the healthy male Sprague-Dawley rats were randomly divided into the blank group, hyperuricemia group allopurinol group as well as low, moderate and high dose groups of Atractylodes macrocephala decoction (N=8 rats in each group). Serum, liver and kidney tissue samples were collected from each group. Serum uric acid (UA), adenosine deaminase (ADA) and xanthine oxidase (XOD) levels in each group were detected by enzyme-linked immunosorbent assay (ELISA). Protein levels of ADA and XOD in liver tissues were detected by Western blot, and renal histological changes were observed by Hematoxylin-eosin (H&E) and Masson staining. In order to investigate the anti-inflammatory effect of Atractylodes macrocephala, the healthy male Sprague-Dawley rats were randomly divided into the blank group, GA group, colchicine group, high, moderate and low dose groups of Atractylodes macrocephala decoction (N=8 rats in each group), and serum and synovial tissue of each group were collected. Then the level of serum interleukin (IL)-1β and tumor necrosis factor (TNF)-α was observed by ELISA, and the histological changes of synovial tissue were observed by H&E staining. Besides, the expression of adenosine monophosphate- activated protein kinase (AMPK) /silent information regulator (SIRT) 1/ nuclear factor kappa B (NF-κB) protein in synovial tissue was observed by Western blot and immunohistochemistry. The markers of M1 and M2 macrophages, inducible nitric oxide synthase (iNOS) and arginase-1 (ARG1) were observed by Western blot and immunofluorescence.
Results: Atractylodes macrocephala could reduce the production of UA by inhibiting the level of ADA and XOD, and could improve renal injury and fibrosis. In addition, Atractylodes macrophages could reduce the levels of IL-1β and TNF-α, activate AMPK/SIRT1 signaling pathway, and inhibit the activation of NF-κB and the polarization of macrophages to a pro-inflammatory phenotype.
Conclusion: Atractylodes macrocephala shows good anti-hyperuricemic and anti-inflammatory effects, and its anti-inflammation pharmacological activity may be related to the inhibition of M1 macrophage polarization and NF-κB activation through activating AMPK/SIRT1.
Keywords: Atractylodes macrocephala, Hyperuricemia, Gouty arthritis, AMPK, SIRT1, NF-κB, Macrophage polarization.
Graphical Abstract
[http://dx.doi.org/10.1016/j.amjmed.2011.09.033] [PMID: 22626509]
[http://dx.doi.org/10.7861/clinmedicine.17-1-54] [PMID: 28148582]
[PMID: 26185426]
[http://dx.doi.org/10.1016/j.molmed.2017.06.005] [PMID: 28732688]
[http://dx.doi.org/10.1016/j.jare.2017.04.008] [PMID: 28748116]
[http://dx.doi.org/10.2165/11592290-000000000-00000] [PMID: 21812506]
[http://dx.doi.org/10.1002/art.39799] [PMID: 27389665]
[http://dx.doi.org/10.1038/nrrheum.2015.132] [PMID: 26416594]
[http://dx.doi.org/10.1002/acr.24180] [PMID: 32391934]
[http://dx.doi.org/10.3109/15563650.2010.495348] [PMID: 20586571]
[http://dx.doi.org/10.1155/2018/8591349] [PMID: 30538765]
[http://dx.doi.org/10.1186/s13020-020-0297-y] [PMID: 32082411]
[http://dx.doi.org/10.1016/j.phymed.2018.11.032] [PMID: 31005813]
[http://dx.doi.org/10.1016/j.jplph.2018.08.006] [PMID: 30144693]
[http://dx.doi.org/10.1016/j.biopha.2020.110554] [PMID: 32890964]
[http://dx.doi.org/10.3390/ijms20194921]
[http://dx.doi.org/10.1093/nar/gkz141] [PMID: 30820544]
[http://dx.doi.org/10.1007/s10787-018-00555-4] [PMID: 30600470]
[http://dx.doi.org/10.1186/s12916-017-0922-5] [PMID: 28818081]
[http://dx.doi.org/10.3389/fphar.2020.566611] [PMID: 33101025]
[http://dx.doi.org/10.1007/s00109-014-1236-0] [PMID: 25475742]
[http://dx.doi.org/10.1093/rheumatology/kez165] [PMID: 31106362]
[http://dx.doi.org/10.1039/C6FO01561A] [PMID: 28428988]
[http://dx.doi.org/10.1142/S0192415X16500531] [PMID: 27430917]
[http://dx.doi.org/10.1016/j.fct.2013.11.022] [PMID: 24287205]
[http://dx.doi.org/10.1097/HJH.0b013e328303205d] [PMID: 18622246]
[http://dx.doi.org/10.1142/S0192415X06003655] [PMID: 16437741]
[http://dx.doi.org/10.1016/j.jep.2018.04.025] [PMID: 29679725]
[http://dx.doi.org/10.1155/2020/4367347] [PMID: 33062010]
[PMID: 24620698]
[http://dx.doi.org/10.1016/j.biochi.2018.07.015] [PMID: 30059711]
[http://dx.doi.org/10.1186/s12906-017-1955-1] [PMID: 28874151]
[http://dx.doi.org/10.1016/j.taap.2018.05.010] [PMID: 29763636]
[http://dx.doi.org/10.1155/2019/2969364] [PMID: 31871475]
[PMID: 14513804]
[http://dx.doi.org/10.1016/j.jep.2018.08.023] [PMID: 30130541]
[http://dx.doi.org/10.1016/j.ejphar.2009.04.001] [PMID: 19356732]
[http://dx.doi.org/10.3390/molecules24162956] [PMID: 31443182]
[http://dx.doi.org/10.1016/j.ejphar.2020.173735] [PMID: 33220271]
[http://dx.doi.org/10.1186/s40360-020-0386-7] [PMID: 32041665]
[http://dx.doi.org/10.1016/j.arr.2011.12.005] [PMID: 22186033]
[http://dx.doi.org/10.1136/annrheumdis-2014-206074] [PMID: 25362043]
[http://dx.doi.org/10.1016/j.tem.2013.12.001] [PMID: 24388149]
[http://dx.doi.org/10.1016/j.devcel.2008.02.004] [PMID: 18477450]
[http://dx.doi.org/10.1074/jbc.M112.355420] [PMID: 22689577]
[http://dx.doi.org/10.1007/s11010-016-2807-x] [PMID: 27613163]
[http://dx.doi.org/10.1007/s00011-021-01439-0] [PMID: 33559709]
[http://dx.doi.org/10.1111/imm.12910] [PMID: 29455468]
[http://dx.doi.org/10.7150/thno.33908] [PMID: 31281508]